Axel Karow

1.5k total citations · 1 hit paper
22 papers, 692 citations indexed

About

Axel Karow is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Axel Karow has authored 22 papers receiving a total of 692 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 11 papers in Genetics and 4 papers in Molecular Biology. Recurrent topics in Axel Karow's work include Chronic Myeloid Leukemia Treatments (9 papers), Acute Myeloid Leukemia Research (7 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers). Axel Karow is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), Acute Myeloid Leukemia Research (7 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers). Axel Karow collaborates with scholars based in Germany, Switzerland and Austria. Axel Karow's co-authors include Radek C. Skoda, Pontus Lundberg, Hui Hao-Shen, Ronny Nienhold, Thomas Lehmann, Martin Stern, Jakob Passweg, Christian Beisel, Róbert Královics and Sabine Girsberger and has published in prestigious journals such as Blood, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Axel Karow

19 papers receiving 686 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

2014 401 citations Pontus Lundberg, Axel Karow et al. Blood profile →

Peers

Countries citing papers authored by Axel Karow

Since Specialization

Citations

This map shows the geographic impact of Axel Karow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Karow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Karow more than expected).

Fields of papers citing papers by Axel Karow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Karow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Karow. The network helps show where Axel Karow may publish in the future.

Co-authorship network of co-authors of Axel Karow

This figure shows the co-authorship network connecting the top 25 collaborators of Axel Karow. A scholar is included among the top collaborators of Axel Karow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Axel Karow. Axel Karow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	What about the heart — pediatric ALL survivors show cardiopulmonary limitations in the MinimALL Study 2025 ·European Journal of Pediatrics ·Felix Huber, (unknown), (unknown), (unknown), Edward W. Wild, Nora Naumann‐Bartsch, Axel Karow, Ferdinand Knieling, Joachim Woelfle, Sven Dittrich, (unknown)	0
2	Distribution of BCR::ABL1 Transcript Types and Response to Therapy in Pediatric Patients with Chronic Myeloid Leukemia 2025 ·Journal of Molecular Diagnostics ·Eric Seiser, Yvonne Lisa Behrens, (unknown), (unknown), Axel Karow, Meinolf Suttorp, Markus Metzler, Manuela Krumbholz	0
3	Circulating Tumor DNA in Pediatric Mature B‐Cell Non‐Hodgkin Lymphoma for Genotyping and Minimal Disease Monitoring 2025 ·Pediatric Blood & Cancer ·(unknown), Christine Damm‐Welk, Marius Rohde, Patrick Hundsdörfer, Simon Vieth, Axel Karow, (unknown), Wolfram Klapper, Julia Richter, (unknown), (unknown), Malik Alawi, (unknown), Birgit Burkhardt, Wilhelm Wößmann, (unknown)	0
4	CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast phase 2024 ·Annals of Hematology ·(unknown), (unknown), (unknown), Axel Karow, Thomas Lion, Guranda Chitadze, Meinolf Suttorp, Gunnar Cario, Markus Metzler	2
5	Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: Influence of demographic, pharmacological, and genetic factors in the German CML-PAED cohort 2024 ·Haematologica ·(unknown), (unknown), (unknown), M. Marx, Manfred Rauh, Manuela Krumbholz, Axel Karow, Meinolf Suttorp, Joachim Woelfle, Carlo Maj, Markus Metzler	2
6	Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment 2023 ·BMC Cancer ·(unknown), (unknown), Domenica Saul, Manuela Krumbholz, Romy Loschinski, Martin Böttcher, (unknown), Markus Metzler, Axel Karow, Dimitrios Mougiakakos	2
7	Temporal evolution and differential patterns of cellular reconstitution after therapy for childhood cancers 2023 ·Scientific Reports ·(unknown), Jakob Zierk, (unknown), (unknown), (unknown), Manuela Krumbholz, Markus Metzler, Axel Karow	5
8	Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib 2023 ·Cancer Immunology Immunotherapy ·(unknown), Axel Karow, Kristin Mentz, Martin Böttcher, (unknown), Manuela Krumbholz, Regina Jitschin, Dimitrios Mougiakakos, Markus Metzler	2
9	Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia 2022 ·Frontiers in Oncology ·(unknown), (unknown), Manuela Krumbholz, (unknown), (unknown), Desiree Grabow, Friederike Erdmann, Axel Karow, Markus Metzler, Meinolf Suttorp	4
10	Targeting Telomere Biology in Acute Lymphoblastic Leukemia 2021 ·International Journal of Molecular Sciences ·Axel Karow, Monika Haubitz, Elisabeth Oppliger Leibundgut, (unknown), (unknown), (unknown), Tobias M. Dantonello, Roland A. Ammann, Jochen Roessler, Mutlu Kartal‐Kaess, Alexander Röth, Gabriela M. Baerlocher	10
11	Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase ‐ a comparison of clinical and genetic characteristics 2021 ·British Journal of Haematology ·(unknown), Gudrun Göhring, (unknown), (unknown), Meinolf Suttorp, Markus Metzler, Axel Karow	6
12	Longitudinal Cytokine Profiling Identifies GRO‐α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia 2020 ·HemaSphere ·Nina Friesgaard Øbro, Jacob Grinfeld, Miriam Belmonte, (unknown), Mairi Shepherd, Tata Nageswara Rao, Axel Karow, (unknown), (unknown), E. Joanna Baxter, Jyoti Nangalia, Anna L. Godfrey, Claire Harrison, Juan Li, Radek C. Skoda, Peter J. Campbell, Anthony R. Green, David G. Kent	39
13	Fulminant Essential Thrombocythemia Associated with Acquired Von Willebrand Syndrome and Bleeding Episodes in a 14-year-old Girl 2019 ·Hämostaseologie ·(unknown), (unknown), Sonja Lüer, Peter M. Keller, Johanna A. Kremer Hovinga, Roland A. Ammann, Axel Karow	5
14	Hearing loss and quality of life in survivors of paediatric CNS tumours and other cancers 2018 ·Quality of Life Research ·Annette Weiß, Grit Sommer, Christina Schindera, Laura Wengenroth, Axel Karow, Manuel Diezi, Gisela Michel, Claudia E. Kuehni, (unknown), Roland A. Ammann, Katrin Scheinemann, Marc Ansari, (unknown), Pierluigi Brazzola, Jeanette Greiner, Michael A. Grotzer, Heinz Hengartner, Titus Küehne, Jochen Rößler, Felix Niggli, (unknown), Nicolas von der Weid	10
15	Peripheral blood progenitor cell collection in pediatric patients optimized by high pre-apheresis count of circulating CD34+ cells and high blood flow 2018 ·Bone Marrow Transplantation ·Axel Karow, (unknown), Roland A. Ammann, Gabriela M. Baerlocher, Thomas Pabst, Behrouz Mansouri Taleghani, Jochen Roessler, Kurt Leibundgut	5
16	Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants 2016 ·Leukemia ·Victoria Pastor, Shinsuke Hirabayashi, Axel Karow, Julius Wehrle, Emilia J. Kozyra, Ronny Nienhold, (unknown), Dirk Lebrecht, Ayami Yoshimi, Marena R. Niewisch, Tim Ripperger, Gudrun Göhring, Irith Baumann, Stephan Schwarz, Brigitte Strahm, Christian Flotho, Radek C. Skoda, Charlotte M. Niemeyer, Marcin W. Włodarski	55
17	Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F–driven mouse model of MPNs 2014 ·Blood ·Adrian Duek, Pontus Lundberg, Takafumi Shimizu, Jean Grisouard, Axel Karow, Lucia Kubovčáková, Hui Hao-Shen, Stephan Dirnhofer, Radek C. Skoda	34
18	JAK2 V617F-Mutated Myeloproliferative Neoplasia Developing Five Years after Wild-Type JAK2 Acute Myeloid Leukemia: A Case Report 2012 ·Acta Haematologica ·Sabine Girsberger, Axel Karow, Pontus Lundberg, Stephan Dirnhofer, Thomas Lehmann, Jakob Passweg, André Tichelli, Radek C. Skoda, Alicia Rovó	1
19	Chromosomal aberrations in congenital bone marrow failure disorders—an early indicator for leukemogenesis? 2007 ·Annals of Hematology ·(unknown), Axel Karow, Doris Steinemann, Ludwig Wilkens, Peter Lichter, Cornelia Zeidler, Charlotte M. Niemeyer, Karl Welte, Brigitte Schlegelberger	26
20	Natural history and early diagnosis of LAD-1/variant syndrome 2006 ·Blood ·Taco W. Kuijpers, Robin van Bruggen, Nanne M. Kamerbeek, Anton T. J. Tool, Gönül Hiçsönmez, Aytemiz Gürgey, Axel Karow, Arthur J. Verhoeven, Karl Seeger, Özden Sanal, Charlotte M. Niemeyer, Dirk Roos	76

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact